Clinical trials
Endometrioid Ovarian Cancer clinical trials
Below are recruiting endometrioid ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT05961124RecruitingPhase 2
Lower-dose niraparib to reduce interruptions in ovarian maintenance
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
Toronto, OntarioAges 18 years+ - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85 - NCT06324175Recruiting
Spatial radiogenomics study for ovarian cancer
This study looks at how medical images relate to genetic patterns in high-grade serous ovarian cancer. It may help find better ways to diagnose and treat this specific type of ovarian cancer.
RomaAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT06395844RecruitingPhase 1/Phase 2
NK cell therapy for advanced ovarian cancer
This trial tests a new therapy that uses your own natural killer (NK) cells, modified to better fight cancer and injected directly into your abdomen. It's for people with advanced ovarian cancer who cannot have surgery or whose tumor cannot be fully removed.
Hefei, AnhuiAges 18–70 - NCT06437353RecruitingPhase 2
Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Hefei, AnhuiAges 18–75 - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06640348Recruiting
New blood test for ovarian cancer screening
This study uses a special blood test (SERS) to find tiny signs of ovarian cancer in the blood. It may help diagnose ovarian cancer earlier or more accurately.
Hefei, AnhuiAges 18–70 - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT06855706Recruiting
Personalized physical activity program for ovarian and endometrial cancers
This study tests whether a personalized, automated physical activity program (using a Fitbit and continuous glucose monitor) can improve immune function and health outcomes in people with advanced ovarian, primary peritoneal, fallopian tube, or newly diagnosed endometrial cancer. You'll wear an activity tracker, answer questionnaires, and provide blood and stool samples at Roswell Park.
Buffalo, New YorkAges 18 years+ - NCT06954584RecruitingPhase 3
Fluzoparib with or without bevacizumab or diet for advanced ovarian cancer
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT07100288Recruiting
Study of the ovary ligament in ovarian cancer patients
This trial looks at a specific ligament near the ovary in patients with epithelial ovarian cancer to better understand the disease. It is for people who had surgery with no cancer left behind.
Las Palmas de Gran CanariaAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07472140RecruitingPhase 2/Phase 3
PARP inhibitor with or without anti-angiogenesis drug for ovarian cancer
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Minsk, LesnoyAges 18–75 - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT03878849RecruitingPhase 2
Study drug 2X-121 for ovarian cancer that keeps coming back
This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.
Oklahoma City, OklahomaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT04111978RecruitingPhase 3
Maintenance hormone therapy after ovarian cancer responds
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
GrazAges 18 years+ - NCT05080946RecruitingEarly Phase 1
Aspirin with chemotherapy to improve ovarian tumor immune features
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
Tampa, FloridaAges 18 years+ - NCT05610735RecruitingPhase 1/Phase 2
Study drug combination for ovarian cancer after platinum stops working
This Phase 1/2 trial tests a combination treatment for recurrent ovarian, fallopian tube, or primary peritoneal cancer when platinum chemotherapy stops working. If you qualify, the study aims to control the cancer and see how well the treatment is tolerated.
Louisville, KentuckyAges 18 years+
Hear when a new Endometrioid Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for endometrioid ovarian cancer?
- Yes. Clin2 currently lists 90 recruiting endometrioid ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a endometrioid ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a endometrioid ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.